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Objective: Health anxiety is associated with distress and disability, and overutilization of health services, but it is
not known whether high levels of health anxiety may lead to increased detection of severe diseases such as
cancer. By linking a large population based health study with the national cancer registry, the aim of the study
was to investigate a potential prospective association between health anxiety in men and women and later
cancer detection and tumour metastasis at the time of diagnosis.
Method: A longitudinal study with a 13.2 year follow-up linking the population-based Hordaland Health Study
(HUSK) and the Cancer Registry of Norway (CRN) was conducted. Health anxiety was measured with the
Whiteley Index. Associations were examined through gender stratiﬁed Cox regression analyses adjusted for
relevant covariates.
Results: No association was found between baseline health anxiety and cancer detection for women (adjusted
HR: 1.21, 95% CI: 0.42–3.50), but a positive association was found between health anxiety at baseline and cancer
detection for men (adjusted HR: 1.76, 95% CI: 1.06–2.91). No statistically signiﬁcant association was
demonstrated between health anxiety and cancer metastasis for either gender.
Conclusion: An increased level of health anxiety in men may be advantageous, as it may motivate to self-
examination and healthcare seekingwhendisturbing symptoms arise. Research is needed to investigatewhether
health anxiety has a protective effect on cancer metastasis at the time of detection, or whether health anxiety
increases the risk of over-diagnosis and overtreatment.© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Health anxiety is characterised by a persistent preoccupation of
having or being in the process of developing a seriousmedical condition
or disease [1,2]. Levels of health anxiety extend from mild to severe
forms, and include deﬁned mental disorders such as illness phobia
and hypochondriasis. Persons with high levels of health anxiety are
intensively worried about their health, are preoccupied with bodily
symptoms, and are actively seeking reassurance despite beliefs that
their symptoms are not taken seriously by others. The lifetime
prevalence of health anxiety in the general population has been found
to be around 6%, while the point prevalence is 3.4% [3]. The prevalenceblic Health and Primary Care,
y. Tel.: +47 40 85 76 66.
n).
. This is an open access article underseems to peak in middle age [3]. Health anxiety is considered to be a
long-lasting condition [4], and patients with health anxiety often report
poorer mental and physical functioning than patients with a well-
deﬁned medical condition [4]. Health anxiety also increases the risk
for adverse functional outcomes such as early retirement or departure
from the paid workforce [5]. As the core symptom is fear of presence
or development of a serious and potential life-threatening medical
condition, persons with high levels of health anxiety are excessive
users of health care services, with increased use of primary care,
specialist health care and laboratory tests [4,6–8].
Fear of death is an integral part of health anxiety, and the preoccupa-
tion with potential presence of a serious disease may be an expression
of this fear [9]. Personal experience with serious illness, either one's
own or the illness of a close friend or relative, is a vulnerability factor
for developing health anxiety [7,8]. Several cross-sectional studies
have found more physical illness among individuals with high levelsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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However, the causal direction of this relationship cannot be established
in cross-sectional studies, and high health anxietymay indeed be the re-
sult of direct experience with illness and disease. To the best of our
knowledge, no study has examined whether the direction may go the
other way, thus, or whether individuals with health anxiety have in-
creased risk of developing and detecting a serious medical condition
in the future.
As one of the leading causes of mortality in the western world,
cancer is frequently a speciﬁc subject of health anxiety [10]. Cancer is
strongly associated with increasing age, but some cancer diseases, in
particular those that affect women (such as breast, ovary and cervix
cancer), may also develop in relatively young age [11]. Fear of cancer
may lead to increased health care visits to check and test for bodily
signals suspected by the person to be symptoms of malignant tumours.
This in turnmay lead to detection of cancer tumours thatmay otherwise
go unnoticed, or to detection of tumours beforemetastasis develops. By
linking a large population based health study in Western Norway with
the national cancer registry, we aimed to investigate whether there
may be a prospective association between health anxiety and detec-
tion and medical diagnosis of a cancer tumour. More speciﬁcally, we
wanted to examine whether men and women with high levels of
health anxiety compared with the general male and female popula-
tion have i) higher prevalence of a subsequent incident cancer
diagnosis, and ii) lower risk of tumour metastasis at the time of
diagnosis.Methods
The Hordaland Health Study (HUSK)
HUSK was an epidemiological, population based health study with
data collection conducted between 1997 and 1999 in the Hordaland
County of Western Norway. All individuals born between 1953 and
1957 who lived in Hordaland at the time (N = 29,400) received a
personal invitation to participate in the health study. A total of 18,565
persons (63.1% of the invited) agreed to participate. Data was collected
through physical examinations and a battery of self-report instruments
distributed in two questionnaires. Questionnaire 1 was included with
the invitation to the health study, and was collected at the physical
examination. Questionnaire 2 consisted of two different versions that
each was randomly given to 50% of the participants at the physical
examination. These were returned by mail.Exposure: health anxiety measured with Whiteley Index (WI)
Health anxiety was measured with the Whiteley Index (WI) in
version 1 of Questionnaire 2. WI was developed by Pilowsky and
colleagues in the mid-1960s [12]. It is considered a classic scale for
measuring health anxiety and hypochondriasis, and is widely used.
The scale consists of 14 items, aiming to assess three dimensions of
health anxiety, namely disease phobia, somatic symptoms and disease
conviction. The participants are asked to rate howmuch each statement
describes their healthworries on a 5-point scale labelled as 1 “not at all”,
2 “to some extent”, 3 “moderately”, 4 “to a considerable extent” and 5
“to a great extent”. Studies have differed in the number of WI items
that they have included, and the cut-off that they have used [12–14].
In the present study, we decided on the 90th percentile as the cut-off,
in an attempt to separate men and women with scores that differed
substantially from the common responses, and thus were considered
likely to have higher levels of health anxiety than the general
population. Responses were missing on some of the items among the
participants. For participants who had replied to 9 or more of the 14
items (n = 809) the sum score was imputed as mean score ∗ 14.Outcome: cancer detection and metastasis
The main outcome in the present study was cancer detection,
deﬁned as incident cancer diagnosis 0.5 to 13.2 years after HUSK partic-
ipation. Presence of metastasis at the time of cancer diagnosis was also
included as an outcome. Information on cancer incidence and metasta-
sis was taken from the Cancer Registry of Norway (CRN) [15]. The can-
cer registry was established in 1951, and all hospitals and pathology
laboratories in Norway are legally required to report neoplasms to
CRN. The registry is thus close to complete for the Norwegian popula-
tion [16]. The CRN discriminates between pre-malignant andmalignant
tumours, and classiﬁes the diagnoses according to the ICD-7 system
[17]. The stage of metastasis at time of diagnosis is classiﬁed as local
(within the organ), regional (spread outside the organ, but within the
bodily region), distant (spread outside the bodily region) or unknown.
HUSKparticipantswere linked to CRN through their personal identiﬁca-
tion number.
In the present study, cancer detection was operationalized as the
ﬁrst date of cancer diagnosis in CRN after HUSK participation. Cancer
metastasis was coded as a binary variable: local versus regional/distant.
Cases with unknown cancer metastasis (n = 54) were excluded from
the metastasis analysis.
Covariates
Due to the generally higher incidence of cancer among women
compared to men in this age group [11], we wanted to examine a
potential association between health anxiety and cancer within
each gender separately. We thus conducted the analyses stratiﬁed
by gender. Several covariates that were assessed in HUSK were
included in the analyses. Self-reportedmarital statuswas categorized
as “married/partner”, “unmarried”, “widow/widower”, “divorced”
and “separated”, while the highest achieved educational level was
for the purpose of the present study categorized as: “higher educa-
tion (college/university)”, “high school” and “compulsory school
only”. We also included information about health related behaviour
in terms of physical activity, alcohol consumption and smoking.
Physical activity was coded according to mean hours per week with
physical activity, giving a continuous variable ranging from no
physical activity to more than 3 h a week with hard physical activity
(involving sweating and being out of breath). The measure of alcohol
consumption was based on gender speciﬁc percentiles: 0) abstainer,
i) low consumption (0–33 percentile), ii) moderate consumption
(34 to 66 percentile) and iii) high consumption (67–100 percentile).
Individuals who reported daily use of cigarettes, cigars or pipe were
deﬁned as daily smokers. Some physical measures were also
included, namely body mass index (BMI) and gender speciﬁc
waist–hip ratio (WHR). The participants were also asked about the
presence of the following somatic conditions: heart attack, diabetes,
stroke, multiple sclerosis, angina pectoris or asthma (yes/no). Finally
we include self-reported information regarding the number of 1st
degree relatives (mother, father, sister, brother, child) previously
or currently diagnosed with cancer.
Statistical procedures
The population eligible for inclusion in the present study includes
all of those who received WI in version 1 of Questionnaire 2 in HUSK
(N = 9472), which were randomly distributed to half of the HUSK
participants. The other half of the HUSK participants, who received
version 2 of Questionnaire 2, were thus excluded from all analyses
in the present study. In order to avoid increased health anxiety levels
due to previously diagnosed cancer, we excluded all persons
diagnosed in CRN with cancer before HUSK (n = 130). We also
excluded all individuals diagnosed with cancer during the ﬁrst
6 months after HUSK participation (n = 5) to avoid possible
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cer presence at the time of health survey participation. Further, we
excluded 2294 persons who did not complete theWI, and 26 individ-
uals with missing data on 9 or more items. There was no increased
cancer incidence among non-responders or those with missing
data onWI items (P= .787). Finally, we excluded 10 participants di-
agnosed with benign tumours. Registration of benign tumours in
CRN was not related to health anxiety (P = .811). The ﬁnal sample
consisted of 7007 individuals, 74.0% of those who were given version
1 of HUSK Questionnaire 2. These persons were followed until the
ﬁrst date of cancer diagnosis in CRN, or until 31st December 2010,
giving a follow-up time ranging from 6 months to 13.2 years.
Gender stratiﬁed associations between health anxiety at baseline
and subsequent cancer incidence and metastasis were examined with
Cox proportional regression models in two blocks: i) unadjusted and
ii) adjusted for all covariates. The association estimates are presented
as hazard ratios (HR) with 95% conﬁdence intervals (CI) and P-values.
In the multivariate analyses, listwise deletion was employed for cases
with missing information (between 0.1% and 2.4% of the total sample,
see Table 1). The cumulative hazard of cancer diagnoses by year after
HUSK participation for men and women with scores under and above
the 90th percentile on the Whiteley Index was also plotted in a Nelson–
Aalen survival plot. All analyses were conducted in Stata version 12.
Ethics
The present study was approved by the Regional Ethics Committee
of Western Norway (REK). The linkage between HUSK and the
Norwegian Cancer Registry was approved by REK and the Norwegian
Data Inspectorate. All HUSK participants gave their written informed
consent for linkage with health registries at the time of participation.
Results
Descriptive characteristics of themen andwomen participating in theHUSK study are
given in Table 1. Both cancer incidence and regional/distal metastasis weremore common
among women compared with men (Table 1). During follow-up, 124 (3.4%) of the men
and 187 (5.6%) of the women were diagnosed with incident cancer. Of these, 36 (29.0%)
male and 79 (42.2%) female cancer cases had regional or distant metastasis at the time
of diagnosis (Table 1). There was no difference in mean score and standard deviation
between men and women above the 90th percentile cut-off on WI.
As described in Table 2, health anxiety was signiﬁcantly associated with subsequent
incident cancer in both the unadjusted (P = .009) and adjusted (P = .028) models forTable 1
Descriptive characteristics of male and female HUSK participants. Total N = 7007 and
follow-up: 6 months to 13.2 years.
Men
(n = 3659)
n (%)
Women
(n = 3348)
n (%)
Missing
n (%)
Cancer incidence 124 (3.4) 187 (5.6) –
Cancer metastasisa 36 (29.0) 79 (42.2) –
Mean score WI cut-off (SD)b 37.8 (0.3) 38.0 (0.3) –
Marital status (not married) 986 (27.0) 830 (24.8) –
Education level (higher education) 1377 (37.9) 1143 (34.5) 56 (0.8)
Physical activity (none) 151 (4.1) 83 (2.5) –
Alcohol consumption (high) 1080 (30.0) 829 (25.6) 169 (2.4)
Smoking (yes) 1274 (34.8) 1191 (35.6) –
Obese (yes)c 442 (12.1) 359 (10.8) 7 (0.1)
Abdominal obesity (yes)d 1907 (52.1) 534 (16.0) –
Other somatic conditions (1 or more)e 292 (8.0) 284 (8.5) 15 (0.2)
Cancer in family (yes)f 1118 (30.6) 1170 (35.0) –
a Regional or distal cancer metastasis at time of diagnosis.
b ≥90th percentile score on Whiteley Index.
c BMI N 30.
d WHR N 0.85 for women and WHR N 0.90 for men.
e Conﬁrmation of one ormore of the following conditions: heart attack, angina pectoris,
stroke, diabetes, asthma, and multiple sclerosis.
f Conﬁrmation of cancer among one or more of 1st degree relatives: mother, father,
brother, sister, and child.men. Thus, men with high levels of health anxiety at HUSK participation were found to
have around 80% increased risk for later cancer detection than men with lower levels of
health anxiety. No association between health anxiety and cancer detection was found
for women (unadjusted: P = .951, adjusted: P = .651). The yearly cumulative hazard
for cancer diagnosis for men and womenwith scores under and above the 90th percentile
cut-off on WI is shown in Fig. 1. In terms of regional and distal metastasis, no signiﬁcant
association with health anxiety was found for any of the genders (Table 2). However,
small numbers in these analyses may have obscured the associations of interest.
Discussion
The present study was based on a sample from the general
population linked with a complete, national cancer registry. No
association was found between baseline health anxiety and cancer
incidence for women, but a positive association was found between
health anxiety at baseline and cancer incidence for men. We believe
that it is unlikely that a real difference in cancer incidence between
men with and without high levels of health anxiety exists. The results
may therefore indicate that men with high levels of health anxiety are
more likely to detect a malignant tumour than men with lower levels
of health anxiety.
The gender difference in the association between high levels of
health anxiety and incident cancer in our sample is interesting, and
may perhaps be explained by general gender differences in health
care utilization and cancer detection strategies. Early detection of cancer
increases the chance of survival and curative treatment [18,19].
According to the World Health Organization, population-based
strategies for early detection of cancer consist of two components:
i) public education on how to detectwarning signs of cancer and engage
in adequate and prompt action, and ii) mass population screening [20].
Since 1995–96, Norway has run two nationwide screening programmes
for the most common types of cancer among women. In the breast
cancer screening programme, all Norwegian women aged 50 to 69 are
invited to a mammography examination every second year [21], while
all women between ages 25 and 69 are invited to cytology and HPV
testing every third year in the cervical cancer screening programme
[22]. In our sample, 57% of incident cancers among women were either
breast or cervix cancer. Exclusion of these cases did not change the
results for women in a sensitivity analysis (data not shown). Thus, the
general invitation to cancer screening may reduce the importance of
health anxiety as a driver for individual cancer detection strategies
among Norwegian women.
In contrast, similar screening programmes for the most common
types of male cancers do not exist to date in Norway. Norwegian men
may thus be left more to themselves in order to detect and report
warning signs of cancer. In general, men consult health care services
less often than women [23], and there is also evidence suggesting that
men tend to engage in less frequent self-examination and delay
reporting of cancer symptoms to their doctors [24]. Therefore, men
with higher levels of health anxiety, who hence are more likely to
have both increased awareness of bodily symptoms and to call upon
their doctors when they discover such symptoms, may be more likely
to detect incident cancer. As such, higher levels of health anxiety may
motivate men to engage in adequate and prompt actions when they
detect unusual and disturbing symptoms.
An obvious continuation of the hypothesis that increased health
anxiety among men leads to improved cancer detection would be to
explore whether increased levels of health anxiety also resulted in less
metastasis at the time of cancer detection. We attempted to examine
this in the present study, but small numbers (only 36men in our sample
were diagnosed with regional/distal cancer metastasis at the time of
diagnosis) precluded any real investigation and interpretation of this
issue. The association between health anxiety and cancer metastasis at
the time of detection is thus an interesting topic for future studies.
Although health anxiety may have a positive consequence in that
tumours are detected early with an increased probability of success-
ful treatment, increased cancer detection may also have important
Table 2
Association between ≥90th percentile score onWhiteley Index at baseline and i) cancer incidence and ii) regional or distant cancer metastasis at time of diagnosis 0.5 to 13.2 years after
HUSK participation, stratiﬁed by gender (Cox regression analysis).
Men
Cancer incidence Regional or distal cancer metastasisa
Predicting 124 (3.4%) cases among 3659 participants Predicting 36 (1.0%) cases among 3628 participants
HR (95% CI) P-value HR (95% CI) P-value
Unadjusted 1.89 (1.17–3.05) P= .009 1.59 (0.62–4.08) P= .338
Fully adjusted 1.76 (1.06–2.91) P= .028 1.21 (0.42–3.50) P= .728
Women
Cancer incidence Regional or distal cancer metastasisa
Predicting 187 (5.6%) cases among 3348 participants Predicting 79 (2.4%) cases among 3326 participants
HR (95% CI) P-value HR (95% CI) P-value
Unadjusted 1.02 (0.63–1.63) P= .951 0.48 (0.18–1.31) P= .152
Fully adjusted 1.12 (0.69–1.81) P= .651 0.50 (0.18–1.39) P= .184
a Cases with unknown metastasis (n = 53) excluded from analysis.
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ing programmes have showed that screening for cancers (in partic-
ular breast and prostate cancer) may result in overdiagnosis and
overtreatment [25]. Besides allocating resources away from more
useful areas, overtreatment also exposes the individual to unnecessary
harmful effects of the cancer-treatment itself, such as urinary, bowel
and sexual dysfunction in prostate cancer treatment [26], side effects
of chemotherapy [27] and complications of colorectal surgery [28].
Future research should therefore examine whether health anxiety is
associated with overdiagnosis and overtreatment in cancer.
Limitations
The present study examined the prospective association between
health anxiety and cancer in a general population sample in linkage
with a comprehensive national register of objective and quality assured
cancer diagnoses, enabling a follow-up of more than 13 years. Despite
these strengths, the present study also has some important limitations.Fig. 1. Nelson–Aalen survival plots of the yearly cumulative hazard for cancer diagnosis for meFirstly, health anxiety was assessed through self-report with a
screening instrument, and not validated by a health professional. The
ability of WI to separate between “real” and “imagined” illnesses is not
known. It is likely that the experience of “real” and disturbing bodily
symptomsmay increase the scores onWI.We tried to reduce this threat
to the external validity ofWI by excluding all caseswith incident cancer
diagnosed the ﬁrst six months after HUSK participation, and by
adjusting for the most common somatic illnesses in this age-group in
the analyses. Further, the structural validity of WI has been examined
in a range of studies, with mixed ﬁndings (for an overview of some of
these studies, see Table 1 in Veddegjaerde et al. [29]). In a recent
published conﬁrmatory factor (CFA) analysis and item response theory
(IRT) analysis on the HUSK population, it was indicated that the use of
the full and original 14-item WI did not yield a satisfactory CFA ﬁt
[29]. Neither did any of 10 other previously suggested models that
were investigated [29]. Based on IRT and CFA analyses, the use of a 6
item one factor approach was suggested [29]. In the present study, we
did an ad-hoc examination of the analyses using the 6-item shortn and women with scores under and above the 90th percentile on Whiteley Index (WI).
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when using the full compared to the abbreviated version of WI were
found (data not shown). The cut-off based on scores above the 90th per-
centile was somewhat arbitrary, although this was chosen in order to
identify men and women likely to have higher levels of health anxiety
than the general population. Despite these limitations, WI is the most
commonly used screening instrument for health anxiety assessments.
Secondly, self-selection and nonparticipation are always a
challenge to epidemiological studies. A previous study of nonpartic-
ipants in the HUSK sample indicated more nonparticipation both
among individuals with mental health problems and with cancer
[30]. However, nonparticipation is likely to be a greater threat to
studies assessing the prevalence of health conditions than to studies
examining associations between variables. Nonparticipation is thus
less likely to have any substantial impact on the results from the
present study.
Thirdly, cancer is a heterogeneous group of diseases, with different
characteristics and prognoses, and the inclusion of all cancer diagnoses
in a single outcome may preclude important differences between the
different types of cancer diseases. It would have been interesting to
examine the association between health anxiety and different sub-
types of cancer, but low numbers in each cancer category precluded
the opportunity for a thorough examination of this issue in the present
sample.
Finally, the results from the present studymay not be generalized to
other settings. For instance, health anxiety among women could be a
more important contributor to cancer detection in countries that do
not have mass screening programmes for breast and cervix cancer.
Likewise, the results may not generalize to settings that have cancer-
screening programmes for men. Furthermore, generalizations to other
age-groups should be done with caution. In Norway, as in many other
high income countries, the vast majority of cancer cases are diagnosed
in persons aged 50 or more, and cancer is in general more common
among men than women, except in the age-group 25 to 49 [31]. Thus,
health anxiety may show different associations with cancer detection
in age-groups where male cancer is more prevalent.
Conclusion
High levels of health anxiety in men were associated with
subsequent detection of cancer. A certain level of health anxiety in
men may thus be advantageous, as it may motivate them to engage in
self-examination of cancer symptoms and healthcare seeking when
such symptoms are discovered. However, health anxiety may also
increase the risk of overdiagnosis and overtreatment in cancer.
Research is needed to investigate whether health anxiety has a protec-
tive effect on cancer metastasis at the time of detection, whether the
association between health anxiety and cancer differs between cancer
diseases, and whether health anxiety is associated with overdiagnosis
and overtreatment in cancer.
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